NLRX1 regulates effector and metabolic functions of CD4+ T cells

Journal of Immunology

Volumn 198, Issue 6, 2017, Pages 2260-2268

  Leber, Andrew ^a   Hontecillas, Raquel ^a   Tubau Juni, Nuria ^a   Zoccoli Rodriguez, Victoria ^a   Hulver, Matthew ^b   McMillan, Ryan ^b   Eden, Kristin ^a,c   Allen, Irving C ^c   Bassaganya Riera, Josep ^a  

^a VIRGINIA BIOINFORMATICS INSTITUTE   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^c VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID BINDING PROTEIN 4; GAMMA INTERFERON; GLUCOSE TRANSPORTER 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; LACTATE DEHYDROGENASE; MESSENGER RNA; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN; NUCLEOTIDE OLIGOMERIZATION DOMAIN LIKE RECEPTOR X1; PATTERN RECOGNITION RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; DEXTRAN SULFATE; MITOCHONDRIAL PROTEIN; NLRX1 PROTEIN, MOUSE;

ANAEROBIC METABOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION ASSAY; CELL METABOLISM; CONTROLLED STUDY; CPT1A GENE; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; DISEASE ACTIVITY; DISEASE SEVERITY; EFFECTOR CELL; ENZYME ACTIVITY; FABP4 GENE; FATTY ACID OXIDATION; GENE; GENE EXPRESSION; GLUT1 GENE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LAMINA PROPRIA; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SPLEEN; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; WILD TYPE; ADOPTIVE TRANSFER; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL PROLIFERATION; CHEMICALLY INDUCED; CITROBACTER RODENTIUM; COLITIS; DISEASE MODEL; ENTEROBACTERIACEAE INFECTION; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASE; KNOCKOUT MOUSE; METABOLISM; TH2 CELL;

ADOPTIVE TRANSFER; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CITROBACTER RODENTIUM; COLITIS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; ENTEROBACTERIACEAE INFECTIONS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERFERON-GAMMA; INTERLEUKIN-17; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOCHONDRIAL PROTEINS; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85014735324     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1601547     Document Type: Article

References (54)

1. Coutermarsh-Ott, S., A. Simmons, V. Capria, T. LeRoith, J. E. Wilson, B. Heid, C. W. Philipson, Q. Qin, R. Hontecillas-Magarzo, J. Bassaganya-Riera, et al. 2016. NLRX1 suppresses tumorigenesis and attenuates histiocytic sarcoma through the negative regulation of NF-kB signaling. Oncotarget 7: 33096-33110.
2. Moore, C. B., D. T. Bergstralh, J. A. Duncan, Y. Lei, T. E. Morrison, A. G. Zimmermann, M. A. Accavitti-Loper, V. J. Madden, L. Sun, Z. Ye, et al. 2008. NLRX1 is a regulator of mitochondrial antiviral immunity. Nature 451: 573-577.
3. Philipson, C. W., J. Bassaganya-Riera, M. Viladomiu, B. Kronsteiner, V. Abedi, S. Hoops, P. Michalak, L. Kang, S. E. Girardin, and R. Hontecillas. 2015. Modeling the regulatory mechanisms by which NLRX1 modulates innate immune responses to Helicobacter pylori infection. PLoS One 10: e0137839.
4. Allen, I. C., C. B. Moore, M. Schneider, Y. Lei, B. K. Davis, M. A. Scull, D. Gris, K. E. Roney, A. G. Zimmermann, J. B. Bowzard, et al. 2011. NLRX1 protein attenuates inflammatory responses to infection by interfering with the RIG-I-MAVS and TRAF6-NF-kB signaling pathways. Immunity 34: 854-865.
5. Guo, H., R. König, M. Deng, M. Riess, J. Mo, L. Zhang, A. Petrucelli, S. M. Yoh, B. Barefoot, M. Samo, et al. 2016. NLRX1 sequesters STING to negatively regulate the interferon response, thereby facilitating the replication of HIV-1 and DNA viruses. Cell Host Microbe 19: 515-528.
6. Jaworska, J., F. Coulombe, J. Downey, F. Tzelepis, K. Shalaby, I. Tattoli, J. Berube, S. Rousseau, J. G. Martin, S. E. Girardin, et al. 2014. NLRX1 prevents mitochondrial induced apoptosis and enhances macrophage antiviral immunity by interacting with influenza virus PB1-F2 protein. Proc. Natl. Acad. Sci. USA 111: E2110-E2119.
7. Xia, X., J. Cui, H. Y. Wang, L. Zhu, S. Matsueda, Q. Wang, X. Yang, J. Hong, Z. Songyang, Z. J. Chen, and R. F. Wang. 2011. NLRX1 negatively regulates TLRinduced NF-kB signaling by targeting TRAF6 and IKK. Immunity 34: 843-853.
8. Koblansky, A. A., A. D. Truax, R. Liu, S. A. Montgomery, S. Ding, J. E. Wilson, W. J. Brickey, M. Muhlbauer, R. M. McFadden, P. Hu, et al. 2016. The innate immune receptor NLRX1 functions as a tumor suppressor by reducing colon tumorigenesis and key tumor-promoting signals. Cell Rep. 14: 2562-2575.
9. Tattoli, I., L. A. Carneiro, M. Jéhanno, J. G. Magalhaes, Y. Shu, D. J. Philpott, D. Arnoult, and S. E. Girardin. 2008. NLRX1 is a mitochondrial NOD-like receptor that amplifies NF-kappaB and JNK pathways by inducing reactive oxygen species production. EMBO Rep. 9: 293-300.
10. Tattoli, I., S. A. Killackey, E.G. Foerster, R.Molinaro, C. Maisonneuve, M.A. Rahman, S. Winer, D. A. Winer, C. J. Streutker, D. J. Philpott, and S. E. Girardin. 2016. NLRX1 acts as an epithelial-intrinsic tumor suppressor through the modulation of TNF-mediated proliferation. Cell Rep. 14: 2576-2586.
11. Belkaid, Y., and B. T. Rouse. 2005. Natural regulatory T cells in infectious disease. Nat. Immunol. 6: 353-360.
12. Carbo, A., R. Hontecillas, B. Kronsteiner, M. Viladomiu, M. Pedragosa, P. Lu, C. W. Philipson, S. Hoops, M. Marathe, S. Eubank, et al. 2013. Systems modeling of molecular mechanisms controlling cytokine-driven CD4+ T cell differentiation and phenotype plasticity. PLoS Comput. Biol. 9: e1003027.
13. Khader, S. A., S. L. Gaffen, and J. K. Kolls. 2009. Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol. 2: 403-411.
14. Tlaskalová-Hogenová, H., R. Stepánková , T. Hudcovic, L. Tucková , B. Cukrowska, R. Lodinová-Zádníková, H. Kozáková, P. Rossmann, J. Bártová, D. Sokol, et al. 2004. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol. Lett. 93: 97-108.
15. Bettelli, E., Y. Carrier, W. Gao, T. Korn, T. B. Strom, M. Oukka, H. L. Weiner, and V. K. Kuchroo. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235-238.
16. Constant, S., C. Pfeiffer, A. Woodard, T. Pasqualini, and K. Bottomly. 1995. Extent of T cell receptor ligation can determine the functional differentiation of naive CD4+ T cells. J. Exp. Med. 182: 1591-1596.
17. Stoll, S., J. Delon, T. M. Brotz, and R. N. Germain. 2002. Dynamic imaging of T cell-dendritic cell interactions in lymph nodes. Science 296: 1873-1876.
18. Leber, A., V. Abedi, R. Hontecillas, M. Viladomiu, S. Hoops, S. Ciupe, J. Caughman, T. Andrew, and J. Bassaganya-Riera. 2016. Bistability analyses of CD4+ T follicular helper and regulatory cells during Helicobacter pylori infection. J. Theor. Biol. 398: 74-84.
19. Fox, C. J., P. S. Hammerman, and C. B. Thompson. 2005. Fuel feeds function: energy metabolism and the T-cell response. Nat. Rev. Immunol. 5: 844-852.
20. Macintyre, A. N., V. A. Gerriets, A. G. Nichols, R. D. Michalek, M. C. Rudolph, D. Deoliveira, S. M. Anderson, E. D. Abel, B. J. Chen, L. P. Hale, and J. C. Rathmell. 2014. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab. 20: 61-72.
21. Michalek, R. D., V. A. Gerriets, S. R. Jacobs, A. N. Macintyre, N. J. MacIver, E. F. Mason, S. A. Sullivan, A. G. Nichols, and J. C. Rathmell. 2011. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J. Immunol. 186: 3299-3303.
22. Newton, R., B. Priyadharshini, and L. A. Turka. 2016. Immunometabolism of regulatory T cells. Nat. Immunol. 17: 618-625.
23. Anderson, A. C., N. Joller, and V. K. Kuchroo. 2016. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 44: 989-1004.
24. Gianchecchi, E., D. V. Delfino, and A. Fierabracci. 2013. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun. Rev. 12: 1091-1100.
25. Ueda, H., J. M. Howson, L. Esposito, J. Heward, H. Snook, G. Chamberlain, D. B. Rainbow, K. M. Hunter, A. N. Smith, G. Di Genova, et al. 2003. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423: 506-511.
26. Mueller, D. L. 2010. Mechanisms maintaining peripheral tolerance. Nat. Immunol. 11: 21-27.
27. Nirschl, C. J., and C. G. Drake. 2013. Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin. Cancer Res. 19: 4917-4924.
28. Okazaki, T., I. M. Okazaki, J. Wang, D. Sugiura, F. Nakaki, T. Yoshida, Y. Kato, S. Fagarasan, M. Muramatsu, T. Eto, et al. 2011. PD-1 and LAG-3 inhibitory coreceptors act synergistically to prevent autoimmunity in mice. J. Exp. Med. 208: 395-407.
29. Sartor, R. B. 2006. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol. 3: 390-407.
30. Frisard, M. I., R. P. McMillan, J. Marchand, K. A. Wahlberg, Y. Wu, K. A. Voelker, L. Heilbronn, K. Haynie, B. Muoio, L. Li, and M. W. Hulver. 2010. Toll-like receptor 4 modulates skeletal muscle substrate metabolism. Am. J. Physiol. Endocrinol. Metab. 298: E988-E998.
31. Parry, R. V., J. M. Chemnitz, K. A. Frauwirth, A. R. Lanfranco, I. Braunstein, S. V. Kobayashi, P. S. Linsley, C. B. Thompson, and J. L. Riley. 2005. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25: 9543-9553.
32. Patsoukis, N., K. Bardhan, P. Chatterjee, D. Sari, B. Liu, L. N. Bell, E. D. Karoly, G. J. Freeman, V. Petkova, P. Seth, et al. 2015. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat. Commun. 6: 6692.
33. Nakazawa, A., I. Dotan, J. Brimnes, M. Allez, L. Shao, F. Tsushima, M. Azuma, and L. Mayer. 2004. The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells. Gastroenterology 126: 1347-1357.
34. Totsuka, T., T. Kanai, S. Makita, R. Fujii, Y. Nemoto, S. Oshima, R. Okamoto, A. Koyanagi, H. Akiba, K. Okumura, et al. 2005. Regulation of murine chronic colitis by CD4+CD252 programmed death-1+ T cells. Eur. J. Immunol. 35: 1773-1785.
35. Song, M. Y., C. P. Hong, S. J. Park, J. H. Kim, B. G. Yang, Y. Park, S. W. Kim, K. S. Kim, J. Y. Lee, S. W. Lee, et al. 2015. Protective effects of Fc-fused PD-L1 on two different animal models of colitis. Gut 64: 260-271.
36. Boussiotis, V. A., P. Chatterjee, and L. Li. 2014. Biochemical signaling of PD-1 on T cells and its functional implications. Cancer J. 20: 265-271.
37. Cantó , C., Z. Gerhart-Hines, J. N. Feige, M. Lagouge, L. Noriega, J. C. Milne, P. J. Elliott, P. Puigserver, and J. Auwerx. 2009. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458: 1056-1060.
38. Cedeno-Laurent, F., M. Opperman, S. R. Barthel, V. K. Kuchroo, and C. J. Dimitroff. 2012. Galectin-1 triggers an immunoregulatory signature in Th cells functionally defined by IL-10 expression. J. Immunol. 188: 3127-3137.
39. Francisco, L. M., P. T. Sage, and A. H. Sharpe. 2010. The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 236: 219-242.
40. Locci, M., C. Havenar-Daughton, E. Landais, J. Wu, M. A. Kroenke, C. L.Arlehamn, L. F. Su,R. Cubas, M.M.Davis, A. Sette, et al; International AIDS Vaccine Initiative Protocol C Principal Investigators. 2013. Human circulating PD-1+CXCR32CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity 39: 758-769.
41. Koves, T. R., J. R. Ussher, R. C. Noland, D. Slentz, M. Mosedale, O. Ilkayeva, J. Bain, R. Stevens, J. R. Dyck, C. B. Newgard, et al. 2008. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab. 7: 45-56.
42. Adams, S. H., C. L. Hoppel, K. H. Lok, L. Zhao, S. W. Wong, P. E. Minkler, D. H. Hwang, J. W. Newman, and W. T. Garvey. 2009. Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J. Nutr. 139: 1073-1081.
43. Imbeault, E., T. M. Mahvelati, R. Braun, P. Gris, and D. Gris. 2014. Nlrx1 regulates neuronal cell death. Mol. Brain 7: 90.
44. McNamee, E. N., D. Korns Johnson, D. Homann, and E. T. Clambey. 2013. Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function. Immunol. Res. 55: 58-70.
45. Dang, E. V., J. Barbi, H. Y. Yang, D. Jinasena, H. Yu, Y. Zheng, Z. Bordman, J. Fu, Y. Kim, H. R. Yen, et al. 2011. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell 146: 772-784.
46. Wang, H., H. Flach, M. Onizawa, L. Wei, M. T. McManus, and A. Weiss. 2014. Negative regulation of Hif1a expression and TH17 differentiation by the hypoxia-regulated microRNA miR-210. Nat. Immunol. 15: 393-401.
47. Xu, Y., A. Chaudhury, M. Zhang, B. Savoldo, L. S. Metelitsa, J. Rodgers, J. T. Yustein, J. R. Neilson, and G. Dotti. 2016. Glycolysis determines dichotomous regulation of T cell subsets in hypoxia. J. Clin. Invest. 126: 2678-2688.
48. Berta, M. A., N. Mazure, M. Hattab, J. Pouysségur, and M. C. Brahimi-Horn. 2007. SUMOylation of hypoxia-inducible factor-1alpha reduces its transcriptional activity. Biochem. Biophys. Res. Commun. 360: 646-652.
49. Ohh, M. 2012. Tumor strengths and frailties: cancer SUMmOns Otto's metabolism. Nat. Med. 18: 30-31.
50. Zhang, R., R. Mehla, and A. Chauhan. 2010. Perturbation of host nuclear membrane component RanBP2 impairs the nuclear import of human immunodeficiency virus-1 preintegration complex (DNA). PLoS One 5: e15620.
51. Eitas, T. K., W. C. Chou, H. Wen, D. Gris, G. R. Robbins, J. Brickey, Y. Oyama, and J. P. Ting. 2014. The nucleotide-binding leucine-rich repeat (NLR) family member NLRX1 mediates protection against experimental autoimmune encephalomyelitis and represses macrophage/microglia-induced inflammation. J. Biol. Chem. 289: 4173-4179.
52. Ina, K., J. Itoh, K. Fukushima, K. Kusugami, T. Yamaguchi, K. Kyokane, A. Imada, D. G. Binion, A. Musso, G. A. West, et al. 1999. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J. Immunol. 163: 1081-1090.
53. Jostins, L., S. Ripke, R. K. Weersma, R. H. Duerr, D. P. McGovern, K. Y. Hui, J. C. Lee, L. P. Schumm, Y. Sharma, C. A. Anderson, et al; International IBD Genetics Consortium (IIBDGC). 2012. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491: 119-124.
54. Seiderer, J., I. Elben, J. Diegelmann, J. Glas, J. Stallhofer, C. Tillack, S. Pfennig, M. Jurgens, S. Schmechel, A. Konrad, et al. 2008. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm. Bowel Dis. 14: 437-445.